1 Min Read
* Dynavax announces FDA approval of Heplisav-B for prevention of Hepatitis B in adults
* Dynavax Technologies Corp - expects to commercially launch Heplisav-B in United States in Q1 of 2018 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.